Pulmonary hypertension is a lethal disease in which inflammation and oxidative stress are deeply involved in the disease state. We have recently screened novel pathogenic molecules and have performed drug discovery targeting those molecules. To confirm its clinical significance, we used patient-derived blood samples to evaluate the potential as a biomarker for diagnosis and prognosis. Finally, we conducted a high-throughput screening and found inhibitors for the pathogenic proteins. In this chapter, we would like to introduce the recent progress on the basic and clinical research focusing on the screening of pathogenic proteins in pulmonary hypertension.
|Title of host publication||Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension|
|Number of pages||5|
|Publication status||Published - 2020 Jan 1|
- Drug discovery
- Pulmonary hypertension
- Transnational research
ASJC Scopus subject areas